PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 174 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $240,000 | +2.1% | 6,178 | +20.6% | 0.01% | 0.0% |
| Q3 2018 | $235,000 | -40.2% | 5,121 | +13.8% | 0.01% | -53.8% |
| Q2 2017 | $393,000 | +30.1% | 4,500 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $302,000 | -14.4% | 4,500 | 0.0% | 0.01% | -27.8% |
| Q4 2015 | $353,000 | +4.1% | 4,500 | 0.0% | 0.02% | 0.0% |
| Q3 2015 | $339,000 | -35.4% | 4,500 | 0.0% | 0.02% | -25.0% |
| Q2 2015 | $525,000 | -50.6% | 4,500 | 0.0% | 0.02% | -50.0% |
| Q1 2015 | $1,062,000 | +24.6% | 4,500 | 0.0% | 0.05% | +20.0% |
| Q4 2014 | $852,000 | -20.7% | 4,500 | 0.0% | 0.04% | -24.5% |
| Q3 2014 | $1,074,000 | +261.6% | 4,500 | 0.0% | 0.05% | +253.3% |
| Q2 2014 | $297,000 | -36.7% | 4,500 | 0.0% | 0.02% | -42.3% |
| Q1 2014 | $469,000 | +0.6% | 4,500 | 0.0% | 0.03% | +13.0% |
| Q4 2013 | $466,000 | +93.4% | 4,500 | 0.0% | 0.02% | +76.9% |
| Q3 2013 | $241,000 | – | 4,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
| Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
| WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
| Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
| Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
| Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
| Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
| Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
| Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |